The U.K.’s MS Trust has been awarded £50,000 (about $65,800) from the Coronavirus Community Support Fund — distributed by…
Articles by Marisa Wexler, MS
The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating…
Eligible people with relapsing-remitting multiple sclerosis (RRMS) now have access to Mavenclad (cladribine) through seven provincial public drug plans in…
A newly identified population of immune cells contributes to inflammation in multiple sclerosis (MS), a new study suggests. The…
A genetic variant may make depression more likely in certain people with multiple sclerosis (MS) than others, a genome-wide study in…
Mayzent (siponimod) has become the first oral medication to be approved for people with active secondary progressive multiple…
Health Canada has approved Zeposia (ozanimod), an oral daily treatment for people with relapsing-remitting multiple sclerosis (RRMS) in…
Connectivity between parts of the brain related to vision and attention is altered in people with relapsing-remitting multiple sclerosis…
Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) are similarly effective at lowering the frequency of relapses and delaying disability…
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application (IND) for ANK-700,…
People in Texas with multiple sclerosis (MS) and other medical conditions now have access to cannabis-infused lozenges,…
More than 2.8 million people worldwide are now estimated to be living with multiple sclerosis (MS), including about 1…
Novartis is not planning to open a clinical trial of Kesimpta (ofatumumab) as a potential treatment for primary progressive multiple…
Upcoming and ongoing clinical trials aim to expand an understanding of Kesimpta (ofatumumab), the Novartis therapy recently approved by the …
Kesimpta (ofatumumab) is a safe and effective treatment for relapsing multiple sclerosis (MS), with an ease of delivery…
MMJ International Holdings, in collaboration with a a specialty pharmaceutical solutions company, has begun manufacturing gelatin…
Chemical modification of the protein eukaryotic elongation factor 1A1 (eEF1A1) regulates remyelination, a new study suggests, indicating that the…
The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for…
Mylan announced the launch of a first generic version of Tecfidera, a treatment for relapsing forms of…
In people with multiple sclerosis (MS), skin cells show increased amounts of cellular stress in a manner that is…
Novartis‘ ofatumumab outperformed Aubagio (teriflunomide) at lowering the frequency of relapses and preventing disability progression among people with…
Immunic Therapeutics‘s IMU-838, a selective immune system modulator, can safely lower the number of brain lesions in…
The Canadian MS Working Group (CMSWG) — made up of neurologists with the Canadian Network of MS Clinics — has…
Low doses of the anesthetic ketamine could help treat fatigue in people with multiple sclerosis (MS), according…
Assessing the cognitive health of people with multiple sclerosis (MS) can be performed using online telehealth, with results…
Treatment with Tysabri (natalizumab) can lessen disability in people with relapsing-remitting multiple sclerosis (RRMS), a large and real-world study found,…
More than half of people with brain imaging changes akin to multiple sclerosis (MS) go on to develop the…
Complementary and alternative medicines are increasingly popular among people with multiple sclerosis (MS) in the northwestern United States, a survey…
JuneBrain, a startup company that is developing a wearable head imaging device that enables multiple sclerosis (MS) patients to…
Tecfidera (dimethyl fumarate) is safe and effective as a long-term treatment for relapsing-remitting multiple sclerosis (RRMS), a study…